Patents Examined by Jennifer Graser
  • Genes of an otitis media isolate of nontypeable
    Patent number: 8283114
    Abstract: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: October 9, 2012
    Assignees: Nationwide Children's Hospital, Inc., The Board of Regents of University of Oklahoma
    Inventors: Lauren O. Bakaletz, Robert S. Munson, Jr., David W. Dyer
  • antigens, vaccine compositions, and related methods
    Patent number: 8277816
    Abstract: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Bacillus anthracis. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: October 2, 2012
    Assignee: Fraunhofer USA, Inc.
    Inventors: Vidadi Yusibov, Vadim Mett, Konstantin Musiychuck, Marina Skarjinskaia
  • Recombinant 15-kDa polypeptide and use of same in detecting human infection with
    Patent number: 8268569
    Abstract: Disclosed are the cloning and expression of a novel antigen of Bartonella henselae. The recombinant polypeptide is found to be highly immunogenic and is useful as a diagnostic test antigen. The polypeptide of the present invention provides the basis of a diagnostic assay that is sensitive, rapid and accurate diagnosis of infection with Bartonella henselae using patient's sera. Disclosed also are the ELISA for both IgG and IgM and allows diagnosis of early and late infection.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: September 18, 2012
    Assignee: Medical Diagnostic Laboratories, L.L.C.
    Inventors: John G. Hoey, Lisa P. Huang, Martin E. Adelson, Eli Mordechai
  • Clostridial toxin NetB
    Patent number: 8263088
    Abstract: The present invention relates to a polypeptide based toxin that originates from Clostridium perfringens. The invention further relates to immunogenic compositions comprising the toxin and methods to vaccinate animals, for example chickens, such that they are less susceptible to clostridial diseases. Methods to determine whether an animal has been exposed to the toxin, polynucleotides encoding the toxin and attenuated bacteria that express a reduced or less active form of the toxin are also disclosed.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: September 11, 2012
    Assignee: Australian Poultry CRC Pty Ltd.
    Inventors: Robert John Moore, Julian Ian Rood, Anthony Leslie Keyburn
  • Vaccine
    Patent number: 8257713
    Abstract: The present invention is concerned with the development of a vaccine against Aeromonas hydrophila for use especially in fish. The invention provides an immunogenic S-layer protein of approximately 50 kDa of A. hydrophila for use in the development of a vaccine, as well as the nucleic acid encoding said protein and vaccines comprising said protein or nucleic acid encoding said protein.
    Type: Grant
    Filed: September 11, 2008
    Date of Patent: September 4, 2012
    Assignee: University of Stirling
    Inventors: Saravanane Poobalane, Kim Thompson, Alexandra Adams
  • Diagnosing pneumococcal pneumonia
    Patent number: 8252546
    Abstract: Compositions and methods for eliciting an immune response against Streptococcus pneumoniae are described. More particularly, the present disclosure relates to immunogenic PcpA polypeptides, including fragments of PcpA and variants thereof, and nucleic acids that encode the polypeptides. The present disclosure further relates to methods of making and using the immunogenic polypeptides. Further provided is a method of diagnosing pneumococcal infection (e.g., pneumonia) in a subject by obtaining a biological sample from the subject and detecting one or more pneumococcal antigens that are selectively expressed during invasion (e.g., PcpA or fragments thereof).
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: August 28, 2012
    Assignee: The UAB Research Foundation
    Inventors: David E. Briles, Susan K. Hollingshead
  • Bacteriocins and novel bacterial strains
    Patent number: 8252291
    Abstract: Novel bacteriocins produced by novel bacterial strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: August 28, 2012
    Assignees: The United States of America, as represented by the Secretary of Agriculture, State Research Center for Applied Microbiology & Biotechnology, Ministry of Health & Social Development, RF, as represented by the Director of the State Research Center for Microbiology & Biotechnology, Ministry of Health & Social Development, RF
    Inventors: Norman J Stern, Edward A Svetoch, Boris V Eruslanov, Vladimir V Perelygin, Vladimir P Levchuk, Nikolay N Urakov, Larisa I Volodina, Yuri N. Kovalev, Tamara Y. Kudryavtseva, Victor D. Pokhilenko, Valery N. Borzenkov, Olga E. Svetoch, Eugeni V. Mitsevich, Irina P. Mitsevich
  • Development of a quail embryo model for the detection of botulinum toxin
    Patent number: 8246931
    Abstract: A method for using bird eggs to detect the presence of at least one botulinum toxin.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: August 21, 2012
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Richard J. Buhr, Dianna V. Bourassa, Larry J. Richardson, Lynda C. Kelley, Nelson A. Cox, Jr., Robert W. Phillips
  • diagnostics and screening methods
    Patent number: 8247181
    Abstract: Compositions and methods of detecting Borrelia proteins, nucleic acid sequences encoding these proteins, and subject antibodies to these proteins in a sample are disclosed.
    Type: Grant
    Filed: September 8, 2008
    Date of Patent: August 21, 2012
    Assignee: The Regents of the University of California
    Inventors: Alan G. Barbour, Philip L. Felgner
  • Method for detection of pneumococcus
    Patent number: 8241857
    Abstract: To provide an immunological detection method which can detect or quantify a pneumococcal antigen in a sample derived from a living body conveniently, rapidly, and with high sensitivity, and an antibody for use in the method. The present invention provides an antibody which specifically recognizes a pneumococcal F-antigen; a method for detecting or quantitating a pneumococcal antigen, characterized in that the method detects or quantitates a pneumococcal F-antigen in a sample derived from a living body through immunological assay employing the antibody; and a kit for detecting a pneumococcal antigen, the kit containing the antibody.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: August 14, 2012
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Suguru Akamatsu, Yoko Saijo
  • Modified flagellin improved toll-like receptor 5 stimulating activity
    Patent number: 8236327
    Abstract: Disclosed herein are flagellin mutants having an enhanced activity of stimulating the toll-like receptor-5 (hereinafter referred to as “TLR5”). More specifically, disclosed are flagellin mutants, prepared by point-mutating some of the amino acids of a TRL5 agonist flagellin so as to enhance the TRL-stimulating activity of the flagellin.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: August 7, 2012
    Assignee: Industry Foundation of Chonnam National University
    Inventors: Joon Haeng Rhee, Shee Eun Lee, Soo Young Kim
  • Genes of an otitis media isolate of nontypeable
    Patent number: 8236494
    Abstract: The invention relates to the polynucleotide sequence of a nontypeable stain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: August 7, 2012
    Assignee: Nationwide Children's Hospital, Inc.
    Inventors: Lauren O. Bakaletz, Robert S. Munson, Jr., David W. Dyer
  • Vaccine compositions
    Patent number: 8226959
    Abstract: The present invention provides methods for the treatment or prevention of allergic airways diseases, the suppression of allergic immune responses, and the induction protective immunity against allergic airways diseases wherein the methods comprise administering to subjects in need thereof an effective amount of a Streptococcus pneumoniae capsular polysaccharide and a Streptococcus pneumoniae exotoxin or exotoxoid, optionally together with one or more additional antigenic or immunomodulatory constituents, components or fractions of Streptococcus pneumoniae and/or immunopotentiators. Administration of individual components is also contemplated. Also provided are vaccine compositions suitable for use in accordance with methods disclosed herein.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: July 24, 2012
    Assignee: Newcastle Innovation Pty Ltd
    Inventors: Peter Gibson, Philip Hansbro
  • Compositions and methods for controlling diseases in animals
    Patent number: 8227235
    Abstract: Disclosed herein are compositions for the treatment of a disease in an animal including yeast extract of Saccharomyces cerevisiae, Bacillus licheniformis or Bacillus subtilis spores, and a carrier. Also included are animal feed compositions including the composition for the prevention, control and/or treatment of a disease in an animal and an animal's food/feed. The compositions are useful to prevent, control, and treat diseases such as necrotic enteritis in poultry when used in combination with an anticoccidal ionophore or coccidiosis vaccine.
    Type: Grant
    Filed: September 21, 2009
    Date of Patent: July 24, 2012
    Assignee: Alpharma, LLC
    Inventors: James Skinner, Doug Rupp
  • Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-neisseria meningitidis
    Patent number: 8221770
    Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtB? is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: July 17, 2012
    Assignee: GlaxoSmithKline Biologicals s.a.
    Inventors: Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
  • Proteins with repetitive Bacterial-Ig-like (Big) domains present in species
    Patent number: 8216594
    Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: July 10, 2012
    Assignees: The United States of America as represented by the Department of Veterans Affairs, The Regents of the University of California, Cornell Research Foundation, Inc.
    Inventors: Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
  • PSM peptides as vaccine targets against methicillin-resistant
    Patent number: 8211445
    Abstract: This disclosure concerns compositions and methods for the treatment and inhibition of infectious disease, particularly methicillin-resistant Staphylococcus. In certain embodiments, the disclosure concerns immunogenic peptides, for instance PSM peptides, which can be used to induce protective immunity against methicillin-resistant Staphylococcus. Also disclosed are methods of detecting methicillin-resistant staphylococcus in a sample, and methods of diagnosing methicillin-resistant staphylococcus in a subject.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: July 3, 2012
    Assignee: The United States of America, as represented by the Department of Health and Human Services
    Inventors: Michael Otto, Rong Wang
  • Methods for diagnosis of and methods and vectors for recombinant toxin expression
    Patent number: 8206940
    Abstract: Cell-based methods for rapid real time assay of a presence of Clostridium difficile toxin and/or cells are provided, using an assay having a toxin-enhancing antibody and a sensitive cell line carrying FcyR receptors, and kits for this assay. An ultrasensitive cell based immunocytotoxicity assay for detecting less then 1 pg/ml of C. difficile toxins in clinical samples. A TcdA-specific monoclonal antibody, AIH3, was found to significantly enhance the cytotoxicity of TcdA to macrophages and monocytes. The AIH3-dependent enhancement of glucosyltransferase activity, cytoskeleton disruption, and TNF-a production induced by TcdA was demonstrated also in RAW 264.7 cells. Methods for high level recombinant expression of C. difficile toxins in Bacillus cells, and vectors for expression, strains of Bacillus carrying the vectors are provided.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: June 26, 2012
    Assignee: Tufts University
    Inventors: Hanping Feng, Saul Tzipori, Guilin Yang
  • Human specific strains
    Patent number: 8178340
    Abstract: The present invention relates to human specific Escherichia coli strains.
    Type: Grant
    Filed: August 13, 2008
    Date of Patent: May 15, 2012
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Olivier Clermont, Erick Denamur, Tony Le Gall, Olivier Tenaillon
  • PheP, an amino acid permease of
    Patent number: 8168204
    Abstract: The present invention relates to antigenic polypeptides expressed by pathogenic microbes, including antigenic polypeptides encoded by the nucleic acid sequence of FIG. 1, vaccines comprising the antigenic polypeptides and therapeutic antibodies directed to the antigenic polypeptides.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: May 1, 2012
    Assignee: Absynth Biologics Ltd.
    Inventor: Simon J. Foster